LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025
Trade with 70% Backtested Accuracy
Analyst Views on LMAT
About LMAT
About the author
LeMaitre Vascular Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Announcement: LeMaitre Vascular has announced that it will release its Q4 2025 financial results on February 25, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Schedule: The company plans to hold a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and outlook, aiming to bolster investor confidence in the company's future direction.
- Registration Details: All registrants will receive dial-in information and a PIN to access the live call, reflecting the company's professionalism and convenience in investor relations.
- Industry Context: LeMaitre Vascular focuses on devices and services for peripheral vascular disease, which affects over 200 million people globally, highlighting the company's significance and potential growth in the medical device market.
LeMaitre Vascular (LMAT): Reevaluating Valuation Following Recent Decline in Share Price
LeMaitre Vascular's Stock Performance: The company's shares are currently trading at $82.95, significantly below previous highs, with a year-to-date return of -9.31% and a 1-year total shareholder return of -21.75%, although long-term holders have seen substantial gains over 3 and 5 years.
Valuation Insights: Analysts peg LeMaitre Vascular's fair value at $104.78, indicating it is undervalued compared to its current price, but the company's high price-to-earnings ratio of 35.3 suggests potential risks if growth expectations are not met.
Growth Drivers: The company is experiencing robust growth in international markets, particularly through new product launches and regulatory approvals, which are expected to create significant new revenue streams.
Risks and Considerations: Emerging risks, such as challenges in maintaining pricing power and execution in new markets, could undermine the optimistic outlook, prompting investors to carefully evaluate the sustainability of the company's growth narrative.
LeMaitre (LMAT) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Reasons for Growth Investors to Consider Buying LeMaitre (LMAT) at This Time
Growth Stock Investment: Investors are increasingly looking for growth stocks that promise above-average returns, but identifying these stocks can be challenging due to their inherent volatility and risk of declining growth.
LeMaitre Vascular Recommendation: LeMaitre Vascular (LMAT) is highlighted as a strong growth stock, boasting a favorable Growth Score and a Zacks Rank of #2, with projected earnings growth of 30.1% this year, significantly outpacing the industry average.
Cash Flow Importance: The company demonstrates impressive cash flow growth at 35.1% year-over-year, which is crucial for funding new projects without relying on external financing, further solidifying its growth potential.
Earnings Estimate Trends: Positive trends in earnings estimate revisions for LeMaitre indicate strong future performance, with a 4.1% increase in current-year earnings estimates over the past month, making it a solid choice for growth investors.
Upcoming Ex-Dividend Dates for CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular
Upcoming Ex-Dividend Dates: CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular will trade ex-dividend on 11/20/25, with respective dividends of $0.22, $0.88, and $0.20 scheduled for payment in December 2025.
Expected Price Adjustments: Following the ex-dividend date, shares of CenterPoint Energy, Regeneron, and LeMaitre Vascular are expected to open lower by approximately 0.55%, 0.12%, and 0.23%, respectively.
Dividend Aristocrats Contender: LeMaitre Vascular is noted as a future contender for the "Dividend Aristocrats" index, having achieved over 14 years of dividend increases.
Current Stock Performance: As of Tuesday trading, CenterPoint Energy and Regeneron shares have increased by 1.1% and 1.6%, while LeMaitre Vascular shares have decreased by 1.6%.
Experts Predict PFM Will Hit $58
ETF Performance Analysis: The Invesco Dividend Achievers ETF (PFM) has an implied analyst target price of $57.76, indicating a potential upside of 12.04% from its current trading price of $51.55.
Notable Holdings with Upside: Key underlying holdings of PFM, such as Brookfield Renewable Partners (BEP), New Jersey Resources Corp (NJR), and LeMaitre Vascular Inc (LMAT), show significant upside potential based on analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with market realities.
Investor Research Importance: It emphasizes the need for further investor research to assess the validity of analyst targets in light of recent company and industry developments.
LeMaitre Vascular Schedules Q4 2025 Earnings Release and Conference Call
- Earnings Release Announcement: LeMaitre Vascular has announced that it will release its Q4 2025 financial results on February 25, 2026, after market close, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Schedule: The company plans to hold a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and outlook, aiming to bolster investor confidence in the company's future direction.
- Registration Details: All registrants will receive dial-in information and a PIN to access the live call, reflecting the company's professionalism and convenience in investor relations.
- Industry Context: LeMaitre Vascular focuses on devices and services for peripheral vascular disease, which affects over 200 million people globally, highlighting the company's significance and potential growth in the medical device market.
LeMaitre Vascular (LMAT): Reevaluating Valuation Following Recent Decline in Share Price
LeMaitre Vascular's Stock Performance: The company's shares are currently trading at $82.95, significantly below previous highs, with a year-to-date return of -9.31% and a 1-year total shareholder return of -21.75%, although long-term holders have seen substantial gains over 3 and 5 years.
Valuation Insights: Analysts peg LeMaitre Vascular's fair value at $104.78, indicating it is undervalued compared to its current price, but the company's high price-to-earnings ratio of 35.3 suggests potential risks if growth expectations are not met.
Growth Drivers: The company is experiencing robust growth in international markets, particularly through new product launches and regulatory approvals, which are expected to create significant new revenue streams.
Risks and Considerations: Emerging risks, such as challenges in maintaining pricing power and execution in new markets, could undermine the optimistic outlook, prompting investors to carefully evaluate the sustainability of the company's growth narrative.
LeMaitre (LMAT) Third Quarter 2025 Earnings Call Summary
- Author's Perspective: The views and opinions presented are solely those of the author.
- No Official Endorsement: The content does not necessarily reflect the views of Nasdaq, Inc.
Reasons for Growth Investors to Consider Buying LeMaitre (LMAT) at This Time
Growth Stock Investment: Investors are increasingly looking for growth stocks that promise above-average returns, but identifying these stocks can be challenging due to their inherent volatility and risk of declining growth.
LeMaitre Vascular Recommendation: LeMaitre Vascular (LMAT) is highlighted as a strong growth stock, boasting a favorable Growth Score and a Zacks Rank of #2, with projected earnings growth of 30.1% this year, significantly outpacing the industry average.
Cash Flow Importance: The company demonstrates impressive cash flow growth at 35.1% year-over-year, which is crucial for funding new projects without relying on external financing, further solidifying its growth potential.
Earnings Estimate Trends: Positive trends in earnings estimate revisions for LeMaitre indicate strong future performance, with a 4.1% increase in current-year earnings estimates over the past month, making it a solid choice for growth investors.
Upcoming Ex-Dividend Dates for CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular
Upcoming Ex-Dividend Dates: CenterPoint Energy, Regeneron Pharmaceuticals, and LeMaitre Vascular will trade ex-dividend on 11/20/25, with respective dividends of $0.22, $0.88, and $0.20 scheduled for payment in December 2025.
Expected Price Adjustments: Following the ex-dividend date, shares of CenterPoint Energy, Regeneron, and LeMaitre Vascular are expected to open lower by approximately 0.55%, 0.12%, and 0.23%, respectively.
Dividend Aristocrats Contender: LeMaitre Vascular is noted as a future contender for the "Dividend Aristocrats" index, having achieved over 14 years of dividend increases.
Current Stock Performance: As of Tuesday trading, CenterPoint Energy and Regeneron shares have increased by 1.1% and 1.6%, while LeMaitre Vascular shares have decreased by 1.6%.
Experts Predict PFM Will Hit $58
ETF Performance Analysis: The Invesco Dividend Achievers ETF (PFM) has an implied analyst target price of $57.76, indicating a potential upside of 12.04% from its current trading price of $51.55.
Notable Holdings with Upside: Key underlying holdings of PFM, such as Brookfield Renewable Partners (BEP), New Jersey Resources Corp (NJR), and LeMaitre Vascular Inc (LMAT), show significant upside potential based on analyst target prices.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with market realities.
Investor Research Importance: It emphasizes the need for further investor research to assess the validity of analyst targets in light of recent company and industry developments.
